Cancer and Immunotherapy Organizations Release Checkpoint Inhibitor Side Effect Guidelines
New guidelines and consensus recommendations for managing immune-related adverse events (irAEs) from checkpoint inhibitors are available from several key cancer and immunotherapy organizations: a collaboration between the American Society of Clinical Oncology and National Comprehensive Cancer Network, and a separate consensus recommendation from the Society for Immunotherapy of Cancer. ONS contributed to the development of both sets of guidelines.
ONS Members Help Define Checkpoint Inhibitor Adverse Event Guidelines
Because the treatment of symptoms, side effects, and adverse events associated with immunotherapies can differ greatly from the standard of care, the American Society of Clinical Oncology (ASCO) and National Comprehensive Cancer Network (NCCN)—along with experts from ONS staff and membership—collaborated to develop guidelines to inform clinicians about managing immune-related adverse events associated with checkpoint inhibitor therapy.
Most Americans Are Unaware of Key Cancer Risk Factors
According to results from the first National Cancer Opinion Survey of 4,016 U.S. adults, the majority of Americans are unaware of several major risk factors for cancer, particularly obesity, which is the second-largest preventable cause of cancer in the United States, after smoking.
ASCO Links Alcohol to Increased Risk for Several Cancers
In a November 2017 special statement, the American Society of Clinical Oncology (ASCO) cited evidence that alcohol consumption directly increases the risk for oropharyngeal and larynx cancer, esophageal cancer, hepatocellular carcinoma, breast cancer, and colon cancer. Although heavy drinking increases risk the most, ASCO noted that even modest consumption puts people at higher risk for these and other cancers. The World Health Organization’s International Agency for Research on Cancer has classified alcohol as a group I carcinogen because it causes cancer in humans.
What Does the Evidence Show About Patient-Reported Outcomes, Quality of Life, and Survival?
Patients know their own experiences best. Evidence has shown that providers are unaware of about half of patients’ symptoms during cancer care. When patients directly report their symptoms using online questionnaires, it can help close this gap in communication. Bringing the patient voice into practice using patient-reported outcomes (PROs) can not only make us aware of their symptoms—enabling earlier interventions—but can also make care delivery more patient-centered.
Data Aggregate System Seeks Oncology Nurse Ambassadors
During a session at the 42nd Annual Congress in Denver, CO—on what happened to be National Nurses Day—the American Society of Clinical Oncology (ASCO) asked nurses to consider joining an initiative intended to gather, collate, and disseminate massive amounts of data to enhance evidence-based cancer diagnosis and treatment.
How ONS and Oncology Nursing Are Helping to Define Big Data and Cancer Care
For oncology nurses, physicians, and care professionals, the importance of implementing tools to collect and analyze big data cannot be understated. Through collaboration and multidisciplinary tactics, data can help drive improvements in the way patients are treated.
Adherence to Nutritional and Physical Activity Guidelines Improves Survival in Patients With Colon Cancer
The American Cancer Society (ACS) has guidelines on nutrition and physical activity for cancer survivors that focus on healthy body weight, physical activity, and a diet high in vegetables, fruits, and whole grains. To assess how adherence to those guidelines impacts disease-free survival (DFS), relapse-free survival (RFS), or overall survival (OS), researchers conducted a prospective study of 992 patients with stage III colon cancer who enrolled in an adjuvant chemotherapy clinical trial between 1991 and 2001. The researchers presented the study at the ASCO Annual Meeting.
ONS and ASCO CancerLinQ Partnership Will Help Institutions Use Practice Data to Drive Greater Cancer Care
Offering personalized treatment plans to patients with cancer is one of the biggest goals for any oncology institution—big or small. ONS leaders and members have united their personal and organizational efforts to move cancer care toward personalization while still aligning the needs of patients with nationally recognized clinical guidelines. Oncology nurses consistently strive to deliver quality cancer care to their patients.
Advancements in Immunotherapy, Genetics Lead ASCO’s Annual Progress Report
Every year, oncology research marches toward new, innovative treatments for patients with cancer. Cancer research is a cumulative process—building upon itself year after year—but, with time, major changes begin to make their way into practices across the country. Some of these advancements stand to change the face of cancer treatment for years to come. In a field of constant evolution, oncology nurses and their colleagues need to stay abreast of developments in science and technology as new knowledge is uncovered in the treatment of cancer.
ASCO Annual Meeting
The American Society of Clinical Oncology (ASCO) Annual Meeting brings together 30,000 oncology professionals from around the world. The theme of the 2016 meeting is Collective Wisdom: The Future of Patient-Centered Care and Research, with a focus on shaping the future of patient care and research through a collaborative approach among healthcare providers.
ONS will be reporting live from the conference in June.